Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehran Makvandi

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|April 13, 2016
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerChristine E Edmonds, Mehran Makvandi, Brian P Lieberman, et al.
Targeted Oncology|February 10, 2018
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical InvestigationsMehran Makvandi, Edouard Dupis, Jonathan W Engle, et al.
Radiology. Imaging Cancer|January 28, 2022
The Development of <sup>18</sup>F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1Hsiaoju S Lee, Sally W Schwarz, Erin K Schubert, et al.
Molecules (Basel, Switzerland)|December 23, 2020
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseAladdin Riad, Sarah B Gitto, Hwan Lee, et al.
Cancer Research|June 5, 2016
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapyMehran Makvandi, Kuiying Xu, Brian P Lieberman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 19, 2022
Imatinib alleviates lung injury and prolongs survival in ventilated ratsYi Xin, Maurizio Cereda, Nadir Yehya, et al.
ACS Pharmacology & Translational Science|February 22, 2021
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of GlioblastomaHannah Dabagian, Tahereh Taghvaee, Paul Martorano, et al.
Bioorganic Chemistry|November 4, 2018
Synthesis and evaluation of an AZD2461 [<sup>18</sup>F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrantSean W Reilly, Laura N Puentes, Alexander Schmitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for NeuroblastomaVandana Batra, Minu Samanta, Mehran Makvandi, et al.
Nuclear Medicine and Biology|October 3, 2019
Improved production of <sup>76</sup>Br, <sup>77</sup>Br and <sup>80m</sup>Br via CoSe cyclotron targets and vertical dry distillationPaul A Ellison, Aeli P Olson, Todd E Barnhart, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
American Journal of Nuclear Medicine and Molecular Imaging|April 13, 2016
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerChristine E Edmonds, Mehran Makvandi, Brian P Lieberman, et al.
Targeted Oncology|February 10, 2018
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical InvestigationsMehran Makvandi, Edouard Dupis, Jonathan W Engle, et al.
Radiology. Imaging Cancer|January 28, 2022
The Development of <sup>18</sup>F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1Hsiaoju S Lee, Sally W Schwarz, Erin K Schubert, et al.
Molecules (Basel, Switzerland)|December 23, 2020
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseAladdin Riad, Sarah B Gitto, Hwan Lee, et al.
Cancer Research|June 5, 2016
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapyMehran Makvandi, Kuiying Xu, Brian P Lieberman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 19, 2022
Imatinib alleviates lung injury and prolongs survival in ventilated ratsYi Xin, Maurizio Cereda, Nadir Yehya, et al.
ACS Pharmacology & Translational Science|February 22, 2021
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of GlioblastomaHannah Dabagian, Tahereh Taghvaee, Paul Martorano, et al.
Bioorganic Chemistry|November 4, 2018
Synthesis and evaluation of an AZD2461 [<sup>18</sup>F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrantSean W Reilly, Laura N Puentes, Alexander Schmitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for NeuroblastomaVandana Batra, Minu Samanta, Mehran Makvandi, et al.
Nuclear Medicine and Biology|October 3, 2019
Improved production of <sup>76</sup>Br, <sup>77</sup>Br and <sup>80m</sup>Br via CoSe cyclotron targets and vertical dry distillationPaul A Ellison, Aeli P Olson, Todd E Barnhart, et al.
Pageof 4